The Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia.
Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.
J Alzheimers Dis. 2024;101(3):737-749. doi: 10.3233/JAD-240241.
Observational Alzheimer's disease (AD) cohorts including the Australian, Biomarkers, Imaging and Lifestyle (AIBL) Study have enhanced our understanding of AD. The generalizability of findings from AIBL to the general population has yet to be studied.
We aimed to compare characteristics of people with AD dementia in AIBL to 1) the general population of older Australians using pharmacological treatment for AD dementia, and to 2) the general population of older Australians who self-reported a diagnosis of dementia.
Descriptive study comparing people aged 65 years of over (1) in AIBL that had a diagnosis of AD dementia, (2) dispensed with pharmacological treatment for AD in Australia in 2021 linked to the Australian census in 2021 (refer to as PBS/census), (3) self-reported a diagnosis of dementia in the 2021 Australian census (refer to as dementia/census). Baseline characteristics included age, sex, highest education attainment, primary language, and medical co-morbidities.
Participants in AIBL were younger, had more years of education, and had a lower culturally and linguistically diverse (CALD) population compared to the PBS/census cohort and dementia/census cohort (mean age±standard deviation - AIBL 79±7 years, PBS/census 81±7, p < 0.001, dementia/census 83±8, p < 0.001; greater than 12 years of education AIBL 40%, PBS/census 35%, p = 0.020, dementia/census 29%, p < 0.001; CALD - AIBL 3%, PBS/census 20%, p < 0.001, dementia/census 22%, p < 0.001).
Our findings suggest that care should be taken regarding the generalizability of AIBL in CALD populations and the interpretation of results on the natural history of AD.
包括澳大利亚、生物标志物、影像和生活方式（AIBL）研究在内的观察性阿尔茨海默病（AD）队列增强了我们对 AD 的认识。然而，AIBL 的研究结果是否适用于普通人群尚待研究。
我们旨在将 AIBL 中 AD 痴呆患者的特征与 1）接受 AD 痴呆药物治疗的澳大利亚老年人群，以及 2）自我报告患有痴呆症的澳大利亚老年人群进行比较。
这是一项描述性研究，比较了 1）AIBL 中年龄在 65 岁及以上且被诊断为 AD 痴呆的患者，2）2021 年在澳大利亚接受 AD 药物治疗且与 2021 年澳大利亚人口普查相关联的人群（称为 PBS/人口普查），3）2021 年澳大利亚人口普查中自我报告患有痴呆症的人群（称为痴呆/人口普查）。基线特征包括年龄、性别、最高教育程度、主要语言和合并症。
与 PBS/人口普查队列和痴呆/人口普查队列相比，AIBL 参与者的年龄更小，受教育程度更高，且文化和语言多样性（CALD）人口比例更低（平均年龄±标准差-AIBL 79±7 岁，PBS/人口普查 81±7，p<0.001，痴呆/人口普查 83±8，p<0.001；受教育程度大于 12 年-AIBL 40%，PBS/人口普查 35%，p=0.020，痴呆/人口普查 29%，p<0.001；CALD-AIBL 3%，PBS/人口普查 20%，p<0.001，痴呆/人口普查 22%，p<0.001）。
我们的研究结果表明，在 CALD 人群中，应谨慎对待 AIBL 的普遍性，并且在解释 AD 自然史的结果时应谨慎。
